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Abstract
Background: Following a stroke, 55–75% of patients experience upper limb problems in the
longer term. Upper limb spasticity may cause pain, deformity and reduced function, affecting mood
and independence. Botulinum toxin is used increasingly to treat focal spasticity, but its impact on
upper limb function after stroke is unclear.
The aim of this study is to evaluate the clinical and cost effectiveness of botulinum toxin type A plus
an upper limb therapy programme in the treatment of post stroke upper limb spasticity.
Methods: Trial design : A multi-centre open label parallel group randomised controlled trial and
economic evaluation.
Participants : Adults with upper limb spasticity at the shoulder, elbow, wrist or hand and reduced
upper limb function due to stroke more than 1 month previously.
Interventions : Botulinum toxin type A plus upper limb therapy (intervention group) or upper limb
therapy alone (control group).
Outcomes : Outcome assessments are undertaken at 1, 3 and 12 months. The primary outcome is
upper limb function one month after study entry measured by the Action Research Arm Test
(ARAT). Secondary outcomes include: spasticity (Modified Ashworth Scale); grip strength;
dexterity (Nine Hole Peg Test); disability (Barthel Activities of Daily Living Index); quality of life
(Stroke Impact Scale, Euroqol EQ-5D) and attainment of patient-selected goals (Canadian
Occupational Performance Measure). Health and social services resource use, adverse events, use
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of other antispasticity treatments and patient views on the treatment will be compared. Participants
are clinically reassessed at 3, 6 and 9 months to determine the need for repeat botulinum toxin
type A and/or therapy.
Randomisation : A web based central independent randomisation service.
Blinding : Outcome assessments are undertaken by an assessor who is blinded to the randomisation
group.
Sample size : 332 participants provide 80% power to detect a 15% difference in treatment successes
between intervention and control groups. Treatment success is defined as improvement of 3 points
for those with a baseline ARAT of 0–3 and 6 points for those with ARAT of 4–56.
Trial registration: ISRCTN78533119
EudraCT 2004-002427-40
CTA 17136/0230/001
Funding: National Institute for Health Research, Health Technology Assessment Programme.
Ipsen Ltd provide botulinum toxin type A (Dysport®).
Background
Upper limb spasticity following stroke
Upper limb impairment affects 85% of stroke patients,
many of whom still experience problems in the longer
term[1,2]. Spasticity can occur following stroke and is
challenging to define and measure. Most recently it has
been described as "disordered sensori-motor control,
resulting from an upper motor neurone lesion, presenting
as intermittent or sustained involuntary activation of
muscles"[3]. An older, narrower and more commonly
quoted definition is " a motor disorder characterised by a
velocity dependent increase in tonic stretch reflexes with
exaggerated tendon reflexes, resulting from hyperexcita-
bility of the stretch reflex"[4]. However, put simply spas-
ticity is over activity of muscles as a result of damage to the
brain or spinal cord. Spasticity can cause pain and
deformity, and in the longer term may lead to the devel-
opment of contractures[5,6]. Upper limb spasticity can
lead to reduced arm function and problems with ease of
hygiene[6]. Effective management of spasticity requires a
coordinated multidisciplinary team approach[6].
Randomised controlled trials of botulinum toxin in the 
treatment of upper limb spasticity following stroke
After injection botulinum toxin causes local paresis of
muscles as a result of blocking cholinergic transmission at
the neuromuscular junction. The clinical treatment effect
lasts for 3–4 months[6]. To date, nine randomised con-
trolled trials have evaluated its use for the treatment of
upper limb spasticity following stroke [7-15], and three
systematic reviews have been published [16-18] (two tri-
als[14,15] and two systematic reviews were published fol-
lowing the start of this study[17,18]).
Trials have reported a measurable reduction in resistance
to passive movement on the Modified Ashworth Scale
within 6 weeks, which then reduces towards 12–16 weeks,
often losing statistical significance at this time. The main
benefits of spasticity reduction appear to be in terms of
global patient/physician ratings and itemised passive dis-
ability scores (notably hand hygiene). Only one study
(published after this study commenced) has reported an
improvement in active upper limb function[15].
As the treatment effect of botulinum toxin lasts only 3–4
months, injections need to be repeated to offer sustained
benefit. Only one trial (published after this study com-
menced) has considered the impact of repeat injec-
tions[14]. This has provided limited evidence to support
continued use of botulinum toxin for spasticity reduction.
Guidelines for the use of botulinum toxin in the treatment
of spasticity recommend that it should be used in combi-
nation with a rehabilitation programme[6], but no trial to
date has attempted to standardise upper limb therapy. No
study has looked at the cost-effectiveness of treatment.
Although transient muscle weakness at higher doses of
botulinum toxin is well recognised, studies reported no
unexpected adverse events, however, the event reporting
system was often unclear.
Participants in previous studies were significantly younger
(average age 52–66 years) than typical stroke patients (the
average incident age of stroke is 75 years) and the studies
were often undertaken in specialist rehabilitation centres.
Multidisciplinary care on a stroke unit is currently the
gold standard for stroke rehabilitation and benefits are
seen regardless of age or stroke severity[19]. Evaluations
of botulinum toxin should recruit participants of all agesTrials 2008, 9:59 http://www.trialsjournal.com/content/9/1/59
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from stroke services rather than tertiary referral centres to
avoid selection bias and ensure results are applicable to
routine care.
The aim of this study is to evaluate the clinical and cost
effectiveness of botulinum toxin type A plus an upper
limb therapy programme in the treatment of post stroke
upper limb spasticity.
Methods
Study design
This is a multi-centre open-label parallel group ran-
domised controlled trial comparing the clinical and cost
effectiveness of botulinum toxin type A plus an upper
limb therapy programme with the upper limb therapy
programme alone for the treatment of upper limb spastic-
ity due to stroke in adults. Figure 1 outlines the study
method.
Primary objective
1. To compare the upper limb function of participants
with spasticity due to stroke who receive botulinum toxin
type A injection(s) to the upper arm and/or forearm flex-
ors/hand/shoulder girdle plus a four week evidence based
upper limb therapy programme (intervention group) with
participants who receive the upper limb therapy pro-
gramme alone (control group) one month after study
entry. Upper limb function is assessed using the Action
Research Arm Test (ARAT)[20].
Secondary objectives
1. To compare the upper limb function and impairment
of participants with spasticity due to stroke who receive
botulinum toxin type A injection(s) to the upper arm and/
or forearm flexors/hand/shoulder girdle plus a four week
evidence based upper limb therapy programme (interven-
tion group) with participants who receive the upper limb
therapy programme (control group) 1, 3 and 12 months
after study entry. Upper limb function and impairment is
assessed by: ARAT[20], Motricity Index[21], grip
strength[22], nine hole peg test[23], and Modified Ash-
worth scale[24].
2. To compare attainment of participant-selected upper
limb goals, disability and stroke related quality of life
between intervention and control groups at 1,3 and 12
months. The following measures are used: attainment of
participant-selected upper limb goals (1 month only) –
Canadian Occupational Performance Measure
(COPM)[25]; disability – Barthel ADL Index[26]; quality
of life – Stroke Impact Scale[27], Euroqol EQ-5D[28],
numerical rating scales for upper limb pain[29].
3. To seek the experience and views of participants about
treatment at 1 and 12 months.
4. To compare the health and social services resources
used by control and intervention groups during the 12
months following study entry.
5. To report adverse events and compare the use of other
antispasticity treatments between intervention and con-
trol groups.
6. To investigate the influence of severity of upper limb
impairment and time since stroke upon the efficacy of the
intervention.
Setting
The study involves a collaborative network of twelve
stroke services in the north of England, with expertise in
the management of spasticity and use of botulinum toxin
being provided by the International Centre for Neurore-
habilitation, Newcastle. We believe that the model which
we have developed i.e. stroke units with close links to a
specialist spasticity service enables all stroke patients to
access specialist care (both in terms of stroke and spastic-
ity management) and this model could be replicated in
other settings.
Case ascertainment
1. Potential participants are identified from a number of
sources in each study centre (stroke unit, out-patients, day
hospital and community rehabilitation teams). He/she is
given an information leaflet and has an opportunity to
discuss the study with a member of the clinical team
(training is given to clinical teams about the project and
research governance). The research team then arranges to
see him/her to discuss the study and seek consent at a
screening visit.
2. There are potential participants who are not currently in
contact with rehabilitation or stroke services. Local com-
munity stroke clubs and day centres have been given
information about the study and individuals may contact
the study directly.
Inclusion criteria
Adults with a stroke greater than 1 month previously who
have moderate/severe spasticity and reduced upper limb
function who fulfil all of following criteria are eligible:
▪ Age over 18 years.
▪ At least 1 month since stroke.
▪ Upper limb spasticity (Modified Ashworth Scale[24] > 2
at the elbow and/or spasticity at the hand, wrist, or shoul-
der (there is no validated measure of spasticity at these
sites)).Trials 2008, 9:59 http://www.trialsjournal.com/content/9/1/59
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Study method Figure 1
Study method.
Participants identified from: 
Stroke services, rehabilitation services, stroke clubs, day centres 
Screening visit 
CENTRAL RANDOMISATION 
Newcastle University 
INTERVENTION 
Botulinum toxin type A + 4 week upper limb therapy 
programme (one hour twice per week provided by study 
therapist)
CONTROL 
4 week upper limb therapy programme (one hour twice per 
week provided by study therapist) 
1 MONTH
Blinded outcome measures  
x Upper limb function – Action Research Arm Test, Nine Hole Peg Test   
x Motor impairment – Motricity Index & grip strength  
x Assessment of spasticity 
x Upper limb pain (numerical rating scale) 
x Patient-selected upper limb goal attainment 
x Disability – Barthel ADL Index 
x Quality of life – Stroke Impact Scale and Euroquol-5D 
3 month
Blinded assessment: outcome measures as above 
Clinical assessment by study therapist.  If required: 
I : further botulinum toxin type A and upper limb therapy. C: further upper limb therapy 
6 month and 9 month
Clinical assessment by study therapist.  If required: 
I : further botulinum toxin type A and upper limb therapy. C: further upper limb therapy 
Initial assessment
12 month
Blinded assessment: outcome measures as above 
Clinical assessment by study therapist.  If further spasticity treatment required, refer to local 
services or regional spasticity clinic  
Target population
Adults with spasticity and reduced upper limb function due to stroke > 1 month 
previously 
Abbreviations:  I intervention     C control Trials 2008, 9:59 http://www.trialsjournal.com/content/9/1/59
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▪ Reduced upper limb function (ARAT[20] score 0–56)
▪ Able to comply with the requirements of the protocol
and upper limb therapy programme.
▪ Informed consent given by participant or legal represent-
ative.
Exclusion criteria
▪ Significant speech or cognitive impairment which
impedes ability to perform the ARAT[20] assessment.
▪ Other significant upper limb impairment e.g. fracture or
frozen shoulder within six months, severe arthritis, ampu-
tation.
▪ Evidence of fixed contracture.
▪ Pregnancy or lactating.
▪ Female at risk of pregnancy and not willing to take ade-
quate precautions against pregnancy for the duration of
the study.
▪ Other diagnosis likely to interfere with rehabilitation or
outcome assessments e.g. registered blind, malignancy.
▪ Other diagnosis which may contribute to upper limb
spasticity e.g. multiple sclerosis, cerebral palsy.
▪ Contraindications to intramuscular injection.
▪ Religious objections to blood products (botulinum
toxin type A (Dysport®) contains human albumin).
▪ Contraindications to botulinum toxin type A which
include bleeding disorders, myasthenia gravis and concur-
rent use of aminoglycosides.
▪ Use of botulinum toxin to the upper limb in the previous
three months.
▪ Known allergy or hypersensitivity to any of the test com-
pounds.
▪ Previous enrolment in this study.
Screening visit
Having sought consent, the screening assessment is com-
pleted by a study therapist or clinical research associate.
The assessment consists of demographic details, review of
medical history and medication; handedness; Abbrevi-
ated Mental Test Score[30], Sheffield Aphasia Screening
Test[31], pre-stroke function (Oxford Handicap
Scale)[32]; time since stroke; stroke type and subtype [33];
self reported current neurological impairment and func-
tion (Barthel ADL Index[26]); quality of life (Euroqol EQ-
5D[28]). Details of current and anti-spasticity treatment
received within the previous 3 months and concomitant
medications are recorded.
Baseline assessment
The baseline visit is undertaken within 2 weeks of the
screening visit by a study therapist or clinical research
associate. The inclusion/exclusion criteria are reviewed to
ensure that the participant is still eligible. Participants
undergo a clinical assessment and are asked to complete a
battery of assessments including: Action Research Arm
Test[20]; Motricity Index[21]; grip strength[22]; Nine
Hole Peg Test[23]; Modified Ashworth Scale[24]; upper
limb pain[29] and Stroke Impact Scale[27]. Patient
selected upper limb goals are also identified (Canadian
Occupational Performance Measure)[25]. Female partici-
pants of child-bearing potential (i.e. those who are not
either surgically sterile or at least 1 year post-last men-
strual period) have a urine pregnancy test, the result of
which must be negative for the participant to be included
in the study. Such participants must agree to use adequate
contraception throughout the study if they are ran-
domised to receive botulinum toxin type A. Participants
are randomised once the baseline assessment has been
completed.
Randomisation
Randomisation is by a central independent web based
randomisation service from the Clinical Trials Unit, New-
castle University. Participants are stratified according to
level of upper limb function (ARAT 0–3, ARAT 4–28,
ARAT 29–56) and randomised to intervention or control
in a 1:1 ratio.
Botulinum toxin
Participants in the intervention group receive botulinum
toxin type A (Dysport®). The range of muscles and dosages
injected are described in 'The management of adults with
spasticity using botulinum toxin: a guide to clinical prac-
tice'[6]. The maximum dose of botulinum toxin type A
(Dysport®) administered at any one time point is 1000
units. All injectors are clinicians trained in the assessment
and injection of botulinum toxin in the context of upper
limb spasticity.
If further treatment is necessary at three, six or nine
months a further injection is provided to those in the
intervention group. At the 12-month review individuals in
both the intervention and control groups who require
botulinum toxin are referred to the spasticity clinic.
If during the course of the trial the study therapist decides
that a participant in the control group has an unaccepta-Trials 2008, 9:59 http://www.trialsjournal.com/content/9/1/59
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ble degree of symptomatic spasticity he/she discusses fur-
ther management with their stroke physician,
physiotherapist, occupational therapist and/or a member
of the local or regional spasticity team and the participant
may then be referred to the spasticity service for botuli-
num toxin.
The upper limb rehabilitation programme
Guidelines highlight that it is important that botulinum
toxin is not used in isolation but as part of a comprehen-
sive upper limb therapy programme[5,6,34]. Focal reduc-
tions in upper limb spasticity from any pharmacological
intervention are unlikely to translate into sustained
improvements in function or patient-selected rehabilita-
tion goals without a targeted therapy programme.
The upper limb therapy programme is based upon availa-
ble research evidence from the stroke rehabilitation and
skill acquisition literature as well as clinical practice [34-
52], and consists of two menus. Participants with ARAT 0–
3 receive menu 1 which is designed specifically for partic-
ipants with no active hand function and focuses on
stretching, passive and active-assisted upper limb move-
ment along with hand hygiene and positioning [42-47].
Menu 2 is for participants with some retained active upper
limb movement (ARAT 4–56) and has been piloted in a
previous study[53]. Following stretching of soft tissues
affected by spasticity, this menu specifically concentrates
on intensive task-orientated practice aimed at patient-cen-
tred goals. Upper limb goals are measured by the Cana-
dian Occupational Performance Measure[25]. Each menu
standardises the category of tasks, the number and order
of repetitions as well as the amount of feedback for each
session, but within these parameters the therapist can tai-
lor the specifics of each activity to the ability of the
patient. Manuals and training programmes have been
developed for both upper limb therapy menus.
The upper limb therapy programme is provided by study
therapists and each participant receives one hour per day,
two times per week for four weeks, in addition to their
other rehabilitation needs. The study therapist may trans-
fer participants between menu 1 and menu 2 according to
their clinical opinion. Participants are given a written
exercise programme to carry out by themselves or with a
carer (following training) on the weekdays they are not
attending therapy.
If the participant is currently receiving rehabilitation, then
the upper limb therapy programme is delivered in that set-
ting e.g. stroke unit, out-patients, day hospital or home. In
each case, the study therapist liaises closely with the reha-
bilitation team to ensure the participant's needs are
addressed and well co-ordinated. At the end of the four
week intervention period patients are given advice by the
study therapist regarding maintaining upper limb func-
tion.
Participants are reviewed by the research team every three
months. If further therapy is required, this is provided by
a study therapist. Those in the intervention group may
also receive a further botulinum toxin type A injection.
Participants in both the intervention and control group
who have symptomatic spasticity at the 12 month follow
up appointment are referred to a spasticity clinic.
Participants who make a good recovery prior to complet-
ing the four week upper limb therapy programme are dis-
charged from the programme provided that they have a
maximum score on the ARAT[20] and have achieved their
upper limb goals.
Outcome assessments
Outcomes are measured by an assessor who is blinded to
the randomisation group one month (+/- 3 days), three
months (+/- 5 days) and twelve months (+/- 5 days) after
the baseline visit. Before contacting the participant a
member of the research team checks with their general
practice or stroke unit that they are still alive and checks
their address. The medical records of participants who
have died are reviewed to seek details of the cause and cir-
cumstances of death, resource utilisation data, and any
potential side effects from botulinum toxin. Each out-
come assessment consists of two stages – stage 1 outcome
assessment by a self completion postal questionnaire
(Barthel ADL Index[26], quality of life (Stroke Impact
Scale[27], Euroqol EQ-5D[28], resource utilisation)
which is sent to participants one week prior to stage 2. Par-
ticipants are asked to bring the completed proforma to
their stage 2 appointment.
Stage 2 outcome assessments consists of assessment of
upper limb impairment and function (ARAT[20], Motric-
ity Index[21], grip strength[22], Nine Hole Peg Test[23],
assessment of spasticity[24] and upper limb pain[29])
and face to face interview seeking participants experience
and views of the study treatment. Information is sought
about side effects, use of other antispasticity treatment
and analgesia for post stroke upper limb pain. Any change
in the participant's concomitant medications since the
previous visit is noted. Any new adverse events or changes
in existing adverse events that have occurred since the pre-
vious visit are sought. The stage 1 questionnaire is checked
for completeness.
Blinding
Outcome assessments are undertaken by an assessor who
is blinded to the randomisation group. To enable blind-
ing to be achieved study therapists undertake screening
and baseline assessments and provide the upper limbTrials 2008, 9:59 http://www.trialsjournal.com/content/9/1/59
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therapy programme in one research centre and undertake
outcome assessments in adjacent centres. At each out-
come assessment he/she is asked to record if he or she had
become unblinded. Participants and the study therapists
who provide the upper limb therapy programme are not
blind to the randomisation group.
Safety evaluation
Side effects of botulinum toxin type A are generally mild
and transient. Local muscle weakness may occur as a
result of toxin spread to nearby muscles. Five per cent
experience flu like symptoms 1 week to 10 days post injec-
tion, dry mouth and pain at the injection site can occur.
Transient dysphagia has been reported. Anaphylaxis rarely
occurs. Excessive doses may produce distant and pro-
found neuromuscular paralysis. Respiratory support may
be required where excessive doses cause paralysis of respi-
ratory muscles. The safety of botulinum toxin type A in
the treatment of participants with upper limb spasticity
post stroke is evaluated by examining the occurrence of all
adverse and serious adverse events as defined by the EU
clinical trial directive[54]. Follow-up of each adverse
event continues until the event or its sequelae resolve or
stabilise at a level that is acceptable to the investigator.
Resource utilisation and economic evaluation
Health and social service resource use associated with bot-
ulinum toxin type A therapy is costed according to estab-
lished methods [55-58]. Measurement and valuation of
resource use is undertaken using a combination of routine
administrative data and primary data collection methods
devised specifically for the study. Costs measured and val-
ued include the costs of the drugs, costs of the upper limb
rehabilitation programme (e.g. staff time) and costs asso-
ciated with any adverse side effects associated with the
administration of the drugs (e.g. general practitioner or
other health care contacts, contacts with social services,
out of pocket payments by participants for pain relieving
drugs). The costs of the drugs is ascertained from suppli-
ers. Staff time is recorded and costed using gross hourly
wage rates derived from the mid-point of appropriate sal-
ary scales. Costs of rehabilitation equipment e.g. upper
limb splinting is obtained from routine data. The fre-
quency of participant contacts with health professionals
and social services is ascertained through the administra-
tion of a participant questionnaire at the 1, 3 and 12
month outcome assessments. Participants are asked about
any contacts they have had with health care professionals
and social services since their last assessment and to indi-
cate any out of pocket expenditure they have incurred for
medication. As the study period is 12 months, there is no
need to apply discounting. The economic evaluation com-
bines the cost data with data on outcomes from the Euro-
qol EQ-5D[28] which is used to estimate the quality
adjusted life years (QALYS) gained from the intervention.
An incremental cost per QALY gained for botulinum toxin
plus upper limb therapy relative to therapy alone will be
estimated and associated cost-effectiveness acceptability
curves presented. Sensitivity analysis will be undertaken
to assess the sensitivity of the results to variations in key
parameters.
Study schedule
Table 1 summarises the study schedule.
Statistical analysis
The primary endpoint is the ARAT[20] score at 1 month.
The analysis will be undertaken on an "intention to treat"
basis; participants will analysed in the group to which
they were randomised.
For each participant it will be determined if there has been
a significant improvement in function based on the
change in ARAT score. A successful outcome will be
defined as:
(i) a change of 3 or more points on the ARAT scale for a
participant whose baseline ARAT score is between 0 and 3
(ii) a change of 6 or more points on the ARAT scale for a
participant whose baseline ARAT score is between 4 and
51
(iii) a final ARAT score of 57 for a participant whose base-
line ARAT score is 52 or greater.
The proportion of "successes" in each group will then be
compared using Fisher's exact test. An interval estimate of
the relative odds of a successful outcome in each group
will also be calculated. This interval estimate of effect size
will be taken forward into the economic evaluation.
Secondary outcomes will also be analysed on an "inten-
tion to treat" basis. A test appropriate to the type of varia-
ble will be undertaken.
A pre-specified sub group analysis will consider the effect
of time since stroke as a covariate. It is hypothesised that
participants who have recently had a stroke will have a
better response to treatment than those who had a stroke
some time ago.
The power calculation used prognosis based methodol-
ogy[59]. A clinically important treatment effect is defined
as a difference in good outcomes between intervention
and control groups of 15% where a good outcome is
defined above for each of the ARAT group; it is expected to
see 20% of the control group achieve good outcomes and
35% of the intervention group achieve good outcomes.
Using Fleiss' method[60] for a binary outcome and inflat-Trials 2008, 9:59 http://www.trialsjournal.com/content/9/1/59
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ing the sample size by 10% to allow for attrition we need
to recruit a total sample of 332 participants to give us 80%
power to detect a 15% difference in good outcomes
assuming a two-tailed test and a significance level of 5%.
We are aiming to recruit 50% of the sample from the
ARAT 0–3 group and 50% from the ARAT 4–56 group.
Current study status
The study commenced recruitment in July 2005 and
achieved target recruitment in March 2008. Participant
follow up was completed in June 2008. The results of the
study will be submitted for publication end 2008.
Amendments to the study since commencement (July 2005)
(1) Objectives
The study protocol includes measurement of spasticity at
the elbow by a biomechanical device which has been used
in a previous pilot study[61]. This was to be used in addi-
tion to clinical measures. Unfortunately the device is not
at a stage of development where it can be used in a mult-
icentre study.
(2) Setting
Initially the trial was planned in 4 geographical areas:
North Tyneside, Wansbeck, Newcastle and Sunderland.
Due to low recruitment rates, further sites were added.
(3) Case ascertainment
This was widened to include identification of participants
from stroke clubs and day centres (in addition to clinical
settings) due to initial low recruitment rates.
(4) Inclusion criteria
Prospective studies of upper limb recovery have shown
that baseline impairment is a strong predictor of outcome.
To demonstrate whether botulinum toxin plus upper limb
Table 1: Study schedule
Time point Screening
< 2 weeks
Baseline
Day 0
Visit 3
Month 11
Visit 4
Month 32
Visit 5
Month 6
Visit 6
Month 9
Visit 7
Month 122
Informed consent X
Record demographics & handedness X
Review inclusion/exclusion criteria X X
Review medical history X X
Details of stroke X
Pre stroke function (inc Oxford Handicap Scale))X
Abbreviated Mental Test Score (AMTS) X
Sheffield Aphasia Screening Test X
Action Research Arm Test (ARAT) X X X X X
Motricity Index X X X X
Grip strength X X X X
Nine Hole Peg Test X X X X
Modified Ashworth Scale X X X X X
Self rating of severity X X X X
Upper limb pain (numerical rating scale)3 XXX X
Patient selects upper limb goals X
Review upper limb goal attainment X
Barthel ADL Index3 XX 3 X3 X3
Quality of life – Stroke Impact Scale3 XX 3 X3 X3
Quality of life – Euroquol-5D3 XX 3 X3 X3
Resource utilisation questions3 XX 3 X3 X3
Pregnancy test4 XX 6 X6 X6
Randomisation X
Treatment with Dysport5 XX 7 X7 X7
Commencement of 4 week upper limb therapy programme X X7 X7 X7
Clinical assessment by study therapist X X X X X
Concomitant medications (inc anti-spasticity treatment) X X X X X
Adverse Events X X X X
Participants views and experience X X
1. Visit window is +3 days.
2. Visit window is +5 days.
3. Questionnaires will be sent to the participant for completion 1 week prior to the visit. Participants will bring completed forms to the visit.
4. For female participants at risk of pregnancy.
5. Participants in the intervention group only.
6. Pregnancy test to be performed prior to any additional botulinum toxin injections.
7. Additional botulinum toxin injections/upper limb therapy to be provided if clinically appropriateTrials 2008, 9:59 http://www.trialsjournal.com/content/9/1/59
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therapy can improve arm function (primary outcome), it
was initially thought important to exclude those partici-
pants with no retained upper limb function (ARAT 0–3).
Due to initial low recruitment, this was later reconsidered
and it was decided that it would be valuable to include
stroke patients with all levels of reduced upper limb func-
tion (ARAT 0–56).
The study also initially excluded participants with cogni-
tive impairment or significant speech problems measured
by the Abbreviated Mental Test Score and Sheffield Apha-
sia Screening Test. This was felt to be too restrictive,
excluding patients who were keen to participate. This
inclusion criteria was relaxed to include all participants
capable of performing the ARAT and complying with the
upper limb therapy programme.
(5) Upper limb therapy programme
A second menu was developed for the upper limb therapy
programme after the eligibility criteria were widened to
include participants with no active upper limb function.
This alternative menu was designed because the original
menu contained activities which these participants would
not have been able to undertake.
(6) Statistical analysis
Inclusion of participants with lower ARAT scores required
revision of the primary analysis and power calculation.
Expert opinion concluded that participants with a base-
line ARAT of 0–3 could not be predicted to improve as
much as those with a baseline ARAT of 4–56. This led to
the definition of successful treatment as improvement by
3 points on the ARAT for those with a starting ARAT of 0–
3 and 6 points by those with a starting ARAT of 4–56.
Comparison of proportions of successes between the
groups (control/intervention) became the primary analy-
sis (as opposed to comparison of absolute ARAT scores in
the initial protocol).
The power calculation was revised for the new binary out-
come.
(7) Follow up period
Participants recruited after 2nd July 2007 were followed for
3 months only. This was a pragmatic decision taken due
to the trial being behind schedule from initial low recruit-
ment rates. Curtailing 12 month follow up allows the trial
to be completed within the initial study timetable. Twelve
month follow up has occurred for 208/333 (62%) partic-
ipants.
Study acronym
BoTULS: Botulinum Toxin for the Upper Limb after Stroke
Ethical arrangements and research governance
The study has MREC, MHRA and local site R+D approvals,
and is being conducted in accordance with ICH-GCP[62],
the UK Medicines for Human Use (Clinical Trials) Regu-
lations 2004[54] and the Research Governance Frame-
work for Health and Social Care[63].
The study has a Data Monitoring and Ethics Committee
(Professor Martin Dennis (chair), University of Edin-
burgh; Professor Ian Ford, University of Glasgow; Profes-
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fessor Bipin Bhakta, University of Leeds; Mrs Beryl
Fairless, lay member, Newcastle upon Tyne; Professor
Gary Ford, Newcastle University; Professor Anne Forster,
University of Leeds; Professor Peter Langhorne (chair),
University of Glasgow; Professor Helen Rodgers, Newcas-
tle University).
The study sponsor is Newcastle Upon Tyne NHS Founda-
tion Trust.
The study is adopted by the UK Stroke Research Network.
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